Side Effects Comparison# Retatrutide Side Effects# Phase 2 trial data revealed: Gastrointestinal : Nausea (24-46%), diarrhea (16-26%), vomiting (9-20%), constipation (6-16%) Heart rate : Small mean increase (2-4 bpm) potentially related to glucagon receptor activation Injection site reactions : Mild and transient Hepatic : Transient elevations in liver enzymes observed Discontinuation rate : 6-10% due to adverse events in Phase 2 The glucagon receptor component introduces a unique side effect profile compared to GLP-1-only or GIP/GLP-1 dual agonists
We also rounded up the best overall protein powders for even more options
Patients entered a 2-week, single-blind run-in treatment period on pre-mixed, long-acting, or intermediate-acting insulin, with or without metformin HCl immediate-release (1500 mg per day)
We tested the effects of a cocktail of 3 and 6 mmol/l AAs
Australia, North America, South America, Western Europe Product Description Retatrutide is an active compound released by Eli Lilly in June 2023